Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...

Scientists from Rice University and their collaborators have unveiled a groundbreaking technique to combat cancer cells, ...

A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...

A collaborative study, published on January 21 on Nature Communications, presents a novel strategy to improve the ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

One of the most significant challenges in cancer treatment is the development of drug resistance by cancer cells, which often leads to treatment failure. When we say the body "resists" cancer ...

Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical ... results from reflux-stimulated production of pro-inflammatory molecules mediated by hypoxia-inducible factors (HIFs).

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...